Molecular-biology markers in the serum of patients with primary bone tu- TOC \o "1-5" \h \z mors

We studied type 1 and 2 fibroblast growth factors (FGF-1, FGF-2) and endostatin in the serum obtained from 58 untreated bone tumor patients and in the serum of 21 practically healthy subjects. FGF-1, FGF-2 and endostatin were measured by enzyme immunoassay in the serum using «R&D» kits (USA). Frequency of FGF-1 determination in serum was in 2,5 times higher in patients with bone tumors than in healthy subjects (p=0,004). All samples contained FGF-2 and endostatin. Endostatin levels in practically healthy subjects were lower than in patients with bone tumors (p=0,005). FGF-1 levels in patients with osteosarcoma were significantly lower than in patients with chondrosarcoma (p<0,05), there were no significant differences in FGF-2 concentrations in patients with various types of affected bone. No significant correlations were found between FGF-1, FGF-2 and endostatin levels in practically healthy subjects and in patients with bone tumors. We demonstrated differences in 3-years overall survival in patients with bone sarcomas depending on serum FGF-1 and endostatin levels.

FGF-1, FGF-2, FGF-1, FGF-2, endostatin, bone tumors, serum